A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

March 23, 2026

Study Completion Date

March 23, 2026

Conditions
Kidney DiseaseGlomerulonephritis
Interventions
DRUG

Mezagitamab

TAK-079 subcutaneous injection.

Trial Locations (26)

100

National Taiwan University Hospital, Taipei

1083

Semmelweis Egyetem, Budapest

3050

Royal Melbourne Hospital, Parkville

3168

Monash Health, Monash Medical Centre, Clayton

4064

Core Research Group, Milton

6720

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged

8025

Fundacio Puigvert, Barcelona

16499

Ajou University Hospital, Suwon

23561

Taipei Medical University Shuang Ho Hospital, New Taipei City

25123

ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia, Brescia

39008

Hospital Universitario Marques de Valdecilla, Santander

60201

NorthShore University HealthSystem, Evanston

83687

Boise Kidney and Hypertension Institute - Frenova, Nampa

91324

Amicis Research Center - Northridge - Nordhoff, Northridge

100050

Beijing Friendship Hospital,Capital Medical University, Beijing

119074

National University Hospital- Singapore, Singapore

510080

Guangdong Provincial Peoples Hospital, Guangzhou

710061

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

486-0804

Kasugai Municipal Hospital, Kasugai-Shi

470-1192

Fujita Health University Hospital, Toyoake-shi

734-8551

Hiroshima University Hospital, Hiroshima

060-8604

Sapporo City General Hospital, Sapporo

03080

Seoul National University Hospital, Seoul

08035

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

LE5 4PW

Leicester General Hospital, Leicester

HU3 2JZ

Hull Royal Infirmary, Hull

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY